BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

China

Datasea Launches Breakthrough Acoustic–AI Healthcare Innovation, Targeting $190 Billion Global Market by 2030

DTSS' Acoustic innovation Addresses the Healthcare Application Market Projected to Exceed $100 Billion in China and Approach $90 B...

August 19, 2025 | News

WuXi XDC Delivers 62% Revenue Growth and Record Project Momentum in H1 2025

- Revenue increased by 62.2% YoY to RMB 2,701 million - Gross profit surged by 82.2% YoY to RMB 975 million, with i...

August 19, 2025 | Company results

Everest Medicines’ Etrasimod (VELSIPITY®) Receives Strong Recommendation in Updated ACG Clinical Guideline for Ulcerative Colitis

Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing, a...

August 18, 2025 | News

Jiangsu Vcare and Huadong Medicine Form Exclusive Partnership for Commercialization of VC005 Tablets in China

Jiangsu Vcare Pharmatech Co., Ltd. (Jiangsu Vcare) announced that it has entered into an exclusive strategic partnership with Huadong Medicine (H...

August 18, 2025 | News

SineuGene Secures Dual U.S. and China IND Clearances for First-in-Class ALS Gene Therapy SNUG01

SineuGene Therapeutics Co., Ltd. ("SineuGene"), clinical-stage biotechnology company that mainly focuses on gene therapies for neurological disorders, anno...

August 18, 2025 | News

Leads Biolabs Completes Patient Enrollment in World’s First Registrational Trial of Immunotherapy for Advanced EP-NEC

Nanjing Leads Biolabs Co., Ltd. ("Leads Biolabs" or the "Company," Stock Code: 9887.HK) announced the successful completion of patient enrollment in t...

August 15, 2025 | News

China’s Biopharma Dealmaking Surges in H1 2025, Driven by Record Licensing and Oncology Focus

The first seven months of 2025 saw robust dealmaking in China’s biopharma and healthcare sector, even as global headwinds tempered some activity. Chi...

August 15, 2025 | Report

Remegen’s Telitacicept Hits Phase III Milestone in Primary Sjögren’s Syndrome

Remegen (688331.SH/09995.HK) announced that its global first-in-class BLyS (BAFF)/APRIL dual-target fusion protein drug, Telitacicept, met the primary endp...

August 14, 2025 | News

Fosun Pharma Licenses XH-S004 to Expedition in US$645M Deal

Fosun Pharma announced that its subsidiary Fosun Pharma Industrial has signed a License Agreement with Expedition Therapeutics Inc.(Expedition) t...

August 13, 2025 | News

WuXi Biologics Achieves Fully Automated Continuous Drug Substance Manufacturing at Pilot Scale with WuXiUP™ Platform

Building on its success in developing continuous production at pilot-scale with the WuXiUP™ platform, WuXi Biologics has further enhanced the ...

August 13, 2025 | News

Mabwell Doses First U.S. Patient in Global Trial of Novel Nectin-4 ADC for Hard-to-Treat Triple-Negative Breast Cancer

Mabwell (688062.SH), an innovative biopharmaceutical company with entire industry chain, announced the first patient dosing in the U.S. for a clinical stud...

August 13, 2025 | News

Chikungunya in China: How a “Forgotten” Arbovirus Found the Perfect Storm

Local health authorities reported thousands of cases within weeks; by early August, figures converged around the several-thousand mark, with some reports t...

August 11, 2025 | Analysis

RemeGen Secures FDA Clearance for Phase II Trials of Innovative Bispecific Antibody RC148 in Advanced Solid Tumors

RemeGen Co., announces clearance of IND application by Food and Drug Administration (FDA) for phase II clinical trials for its independently-developed bisp...

August 11, 2025 | News

GenScript Launches ‘Scripting Possibilities’—A Bold Global Brand Identity to Power the Future of Life Sciences

GenScript Biotech Corporation (HK.1548), a global leader in life sciences innovation, unveiled its new global brand platform: Scripting Possibilities...

August 11, 2025 | News

Stay Connected